Endo gets N. American rights to Vernalis's Frova
Executive Summary
Endo Pharmaceuticals (pain management) has been granted exclusive North American rights to Vernalis PLC's (focused on neurology and oncology) Frova (frovatriptan), which is approved for acute treatment of migraine headaches with or without aura in adults.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice